NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Zafirlukast

Last Revision: May 1, 2019.

Estimated reading time: 1 minute

CASRN: 107753-78-6

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No published information is available on the use of zafirlukast during breastfeeding; however, manufacturer's data indicate that the dose in milk is low. If zafirlukast is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Zafirlukast has been used in children as young as 12 months of age.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

The manufacturer reports that after administration of zafirlukast 40 mg twice daily to lactating women (number not reported), average steady-state milk concentrations were 50 mcg/L.[2] Using these data, a fully breastfed infant would be expected to receive about 0.6% of the maternal weight-adjusted dosage.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10:149-59. [PubMed: 15701580]
2.
Anon. Accolate Package Insert. AstraZeneca Pharmaceuticals. Wilmington DE. 2011.

Substance Identification

Substance Name

Zafirlukast

CAS Registry Number

107753-78-6

Drug Class

  • Breast Feeding
  • Anti-Asthmatic Agents
  • Leukotriene Antagonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Almotriptan[Drugs and Lactation Database (...]
    Review Almotriptan
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ezogabine[Drugs and Lactation Database (...]
    Review Ezogabine
    . Drugs and Lactation Database (LactMed). 2006
  • Identification, characterization and synthesis of impurities of zafirlukast.[J Pharm Biomed Anal. 2009]
    Identification, characterization and synthesis of impurities of zafirlukast.
    Goverdhan G, Reddy AR, Srinivas K, Himabindu V, Reddy GM. J Pharm Biomed Anal. 2009 May 1; 49(4):895-900. Epub 2009 Jan 24.
  • Review Tolazamide[Drugs and Lactation Database (...]
    Review Tolazamide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Valsartan[Drugs and Lactation Database (...]
    Review Valsartan
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...